PMID- 30796037
OWN - NLM
STAT- MEDLINE
DCOM- 20200706
LR  - 20231107
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 25
IP  - 11
DP  - 2019 Jun 1
TI  - Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in 
      Patients with Glioblastoma.
PG  - 3259-3265
LID - 10.1158/1078-0432.CCR-18-3034 [doi]
AB  - PURPOSE: Patients with glioblastoma (GBM) have a poor prognosis and are in 
      desperate need of better therapies. As therapeutic decisions are increasingly 
      guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing 
      a potential therapeutic target, we systematically evaluated methods of assessing 
      EGFR amplification by multiple assays. Specifically, we evaluated correlation 
      among fluorescence in situ hybridization (FISH), a standard assay for detecting 
      EGFR amplification, with other methods.Experimental Design: Formalin-fixed, 
      paraffin-embedded tumor samples were used for all assays. EGFR amplification was 
      detected using FISH (N = 206) and whole-exome sequencing (WES, N = 74). EGFR mRNA 
      expression was measured using reverse transcription-polymerase chain reaction 
      (RT-PCR, N = 206) and transcriptome profiling (RNAseq, N = 64). EGFR protein 
      expression was determined by immunohistochemistry (IHC, N = 34). Significant 
      correlations among various methods were determined using Cohen's kappa (kappa = 
      0.61-0.80 defines substantial agreement) or R (2) statistics. RESULTS: EGFR mRNA 
      expression levels by RNA sequencing (RNAseq) and RT-PCR were highly correlated 
      with EGFR amplification assessed by FISH (kappa = 0.702). High concordance was also 
      observed when comparing FISH to WES (kappa = 0.739). RNA expression was superior to 
      protein expression in delineating EGFR amplification. CONCLUSIONS: Methods for 
      assessing EGFR mRNA expression (RT-PCR, RNAseq) and copy number (WES), but not 
      protein expression (IHC), can be used as surrogates for EGFR amplification (FISH) 
      in GBM. Collectively, our results provide enhanced understanding of available 
      screening options for patients, which may help guide EGFR-targeted therapeutic 
      approaches.
CI  - (c)2019 American Association for Cancer Research.
FAU - Lassman, Andrew B
AU  - Lassman AB
AD  - Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia 
      University Irving Medical Center, New York, New York. ABL7@cumc.columbia.edu.
FAU - Roberts-Rapp, Lisa
AU  - Roberts-Rapp L
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Sokolova, Irina
AU  - Sokolova I
AD  - Abbott Molecular, Inc., Des Plaines, Illinois.
FAU - Song, Minghao
AU  - Song M
AD  - Abbott Molecular, Inc., Des Plaines, Illinois.
FAU - Pestova, Ekaterina
AU  - Pestova E
AD  - Abbott Molecular, Inc., Des Plaines, Illinois.
FAU - Kular, Rupinder
AU  - Kular R
AD  - Abbott Molecular, Inc., Des Plaines, Illinois.
FAU - Mullen, Carolyn
AU  - Mullen C
AD  - Abbott Molecular, Inc., Des Plaines, Illinois.
FAU - Zha, Zheng
AU  - Zha Z
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Lu, Xin
AU  - Lu X
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Gomez, Erica
AU  - Gomez E
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Bhathena, Anahita
AU  - Bhathena A
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Maag, David
AU  - Maag D
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Kumthekar, Priya
AU  - Kumthekar P
AD  - Department of Neurology, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois.
FAU - Gan, Hui K
AU  - Gan HK
AUID- ORCID: 0000-0001-7319-8546
AD  - Austin Health, Olivia Newton-John Cancer Research Institute, and La Trobe 
      University, Melbourne, Victoria, Australia.
FAU - Scott, Andrew M
AU  - Scott AM
AD  - Austin Health, Olivia Newton-John Cancer Research Institute, and La Trobe 
      University, Melbourne, Victoria, Australia.
FAU - Guseva, Maria
AU  - Guseva M
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Holen, Kyle D
AU  - Holen KD
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - Ansell, Peter J
AU  - Ansell PJ
AD  - AbbVie, Inc., North Chicago, Illinois.
FAU - van den Bent, Martin J
AU  - van den Bent MJ
AUID- ORCID: 0000-0001-5710-5127
AD  - Erasmus MC Cancer Center, Rotterdam, the Netherlands.
LA  - eng
SI  - ClinicalTrials.gov/NCT01800695
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30 CA013696/CA/NCI NIH HHS/United States
GR  - P30 CA091842/CA/NCI NIH HHS/United States
GR  - UG1 CA189960/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190222
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - *Biomarkers, Tumor
MH  - Clinical Trials, Phase I as Topic
MH  - ErbB Receptors/genetics/metabolism
MH  - Gene Amplification
MH  - Gene Expression Profiling
MH  - Genetic Testing
MH  - Glioblastoma/diagnosis/*etiology/metabolism/therapy
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Precision Medicine/methods/standards
MH  - Real-Time Polymerase Chain Reaction
MH  - Exome Sequencing
PMC - PMC8291723
MID - NIHMS1522604
EDAT- 2019/02/24 06:00
MHDA- 2020/07/07 06:00
PMCR- 2021/07/20
CRDT- 2019/02/24 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/01/16 00:00 [revised]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2019/02/24 06:00 [pubmed]
PHST- 2020/07/07 06:00 [medline]
PHST- 2019/02/24 06:00 [entrez]
PHST- 2021/07/20 00:00 [pmc-release]
AID - 1078-0432.CCR-18-3034 [pii]
AID - 10.1158/1078-0432.CCR-18-3034 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2019 Jun 1;25(11):3259-3265. doi: 10.1158/1078-0432.CCR-18-3034. 
      Epub 2019 Feb 22.